Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2015 Aug 25;314(8):791-801.
doi: 10.1001/jama.2015.9677.
Affiliations
- PMID: 26305649
- PMCID: PMC5369607
- DOI: 10.1001/jama.2015.9677
Randomized Controlled Trial
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
Emily Y Chew et al. JAMA. 2015.
Abstract
Importance: Observational data have suggested that high dietary intake of saturated fat and low intake of vegetables may be associated with increased risk of Alzheimer disease.
Objective: To test the effects of oral supplementation with nutrients on cognitive function.
Design, setting, and participants: In a double-masked randomized clinical trial (the Age-Related Eye Disease Study 2 [AREDS2]), retinal specialists in 82 US academic and community medical centers enrolled and observed participants who were at risk for developing late age-related macular degeneration (AMD) from October 2006 to December 2012. In addition to annual eye examinations, several validated cognitive function tests were administered via telephone by trained personnel at baseline and every 2 years during the 5-year study.
Interventions: Long-chain polyunsaturated fatty acids (LCPUFAs) (1 g) and/or lutein (10 mg)/zeaxanthin (2 mg) vs placebo were tested in a factorial design. All participants were also given varying combinations of vitamins C, E, beta carotene, and zinc.
Main outcomes and measures: The main outcome was the yearly change in composite scores determined from a battery of cognitive function tests from baseline. The analyses, which were adjusted for baseline age, sex, race, history of hypertension, education, cognitive score, and depression score, evaluated the differences in the composite score between the treated vs untreated groups. The composite score provided an overall score for the battery, ranging from -22 to 17, with higher scores representing better function.
Results: A total of 89% (3741/4203) of AREDS2 participants consented to the ancillary cognitive function study and 93.6% (3501/3741) underwent cognitive function testing. The mean (SD) age of the participants was 72.7 (7.7) years and 57.5% were women. There were no statistically significant differences in change of scores for participants randomized to receive supplements vs those who were not. The yearly change in the composite cognitive function score was -0.19 (99% CI, -0.25 to -0.13) for participants randomized to receive LCPUFAs vs -0.18 (99% CI, -0.24 to -0.12) for those randomized to no LCPUFAs (difference in yearly change, -0.03 [99% CI, -0.20 to 0.13]; P = .63). Similarly, the yearly change in the composite cognitive function score was -0.18 (99% CI, -0.24 to -0.11) for participants randomized to receive lutein/zeaxanthin vs -0.19 (99% CI, -0.25 to -0.13) for those randomized to not receive lutein/zeaxanthin (difference in yearly change, 0.03 [99% CI, -0.14 to 0.19]; P = .66). Analyses were also conducted to assess for potential interactions between LCPUFAs and lutein/zeaxanthin and none were found to be significant.
Conclusions and relevance: Among older persons with AMD, oral supplementation with LCPUFAs or lutein/zeaxanthin had no statistically significant effect on cognitive function.
Trial registration: clinicaltrials.gov Identifier: NCT00345176.
Conflict of interest statement
Conflict of Interest
Emily Y. Chew, Elvira Agrón, and Lenore Launer, are employees of the National Institutes of Health that sponsored the study.
Emily Y. Chew, Elvira Agrón, Traci E. Clemons, Lenore Launer, and Fran Grodstein have no financial or other conflicts of interest.
Paul Bernstein: reported serving as a consultant for Kemin Health, Kalsec, DSM, and Science Based Health.
Figures
Figure 1. CONSORT Figure
The CONSORT Figure Showing the AREDS2 participants Included in the Analyses of the the Ancillary Cognitive Function Study LCPUFAs: Long Chain Polyunsaturated Fatty Acids Reasons for declining consent for the Ancillary Cognitive Function Testing were not collected.
Figure 2
Results of the mixed models regression for the change per year in cognitive function test scores from baseline for each of the nutrients tested: A. Comparison of the main effects of omega-3 LCPUFAs vs. no omega-3 LCPUFAs. LCPUFAs: Long Chain Polyunsaturated Fatty Acids TICS: Telephone Interview of Cognitive Status Composite score. A composite score was constructed by including the score of the TICS and all the cognitive tests by converting all test results into z-scores and then averaging the z-scores. The composite score was computed to obtain an overall score for the battery of cognitive function tests, ranging from −22 to 17, with higher scores representing better function. Telephone Interview Cognitive Status-Modified (TICS-M) is a version of the Mini Mental State Examination. The score for TICS ranges from 0 to 39 points. See supplementary methods for explanation for the scores of the other cognitive function tests. Worse means a deterioration of the score for that given nutrient and better means an improved score for those randomized to omega3 fatty acids, DHA/EPA. These analyses are adjusted for the following baseline covariates: age, gender, race, education, smoking, hypertension, congestive heart failure, and depression scale. B: Comparison of the main effects of lutein/zeaxanthin vs. no lutein/zeaxanthin. Lut/Zea: Lutein/Zeaxanthin TICS: Telephone Interview of Cognitive Status Composite score. A composite score was constructed by including the score of the TICS and all the cognitive tests by converting all test results into z-scores and then averaging the z-scores. The composite score was computed to obtain an overall score for the battery of cognitive function tests, ranging from −22 to 17, with higher scores representing better function. Telephone Interview Cognitive Status-Modified (TICS-M) is a version of the Mini Mental State Examination. The score for TICS ranges from 0 to 39 points. See supplementary methods for explanation for the scores of the other cognitive function tests. Worse means a deterioration of the score for that given nutrient and better means an improved score for those randomized to lutein/zeaxanthin. These analyses are adjusted for the following baseline covariates: age, gender, race, education, smoking, hypertension, congestive heart failure, and depression scale. C: Comparison of the main effects of high zinc vs. low zinc. TICS: Telephone Interview of Cognitive Status Composite score. A composite score was constructed by including the score of the TICS and all the cognitive tests by converting all test results into z-scores and then averaging the z-scores. The composite score was computed to obtain an overall score for the battery of cognitive function tests, ranging from −22 to 17, with higher scores representing better function. Telephone Interview Cognitive Status-Modified (TICS-M) is a version of the Mini Mental State Examination. The score for TICS ranges from 0 to 39 points. See supplementary methods for explanation for the scores of the other cognitive function tests. Worse means a deterioration of the score for that given nutrient and better means an improved score for those randomized to zinc. These analyses are adjusted for the following baseline covariates: age, gender, race, education, smoking, hypertension, congestive heart failure, and depression scale. D: Comparison of the main effects of beta-carotene vs. no beta-carotene. TICS: Telephone Interview of Cognitive Status Composite score. A composite score was constructed by including the score of the TICS and all the cognitive tests by converting all test results into z-scores and then averaging the z-scores. The composite score was computed to obtain an overall score for the battery of cognitive function tests, ranging from −22 to 17, with higher scores representing better function. Telephone Interview Cognitive Status-Modified (TICS-M) is a version of the Mini Mental State Examination. The score for TICS ranges from 0 to 39 points. See supplementary methods for explanation for the scores of the other cognitive function tests. Worse means a deterioration of the score for that given nutrient and better means an improved score for those randomized to beta-carotene. These analyses are adjusted for the following baseline covariates: age, gender, race, education, smoking, hypertension, congestive heart failure, and depression scale.
Figure 2
Results of the mixed models regression for the change per year in cognitive function test scores from baseline for each of the nutrients tested: A. Comparison of the main effects of omega-3 LCPUFAs vs. no omega-3 LCPUFAs. LCPUFAs: Long Chain Polyunsaturated Fatty Acids TICS: Telephone Interview of Cognitive Status Composite score. A composite score was constructed by including the score of the TICS and all the cognitive tests by converting all test results into z-scores and then averaging the z-scores. The composite score was computed to obtain an overall score for the battery of cognitive function tests, ranging from −22 to 17, with higher scores representing better function. Telephone Interview Cognitive Status-Modified (TICS-M) is a version of the Mini Mental State Examination. The score for TICS ranges from 0 to 39 points. See supplementary methods for explanation for the scores of the other cognitive function tests. Worse means a deterioration of the score for that given nutrient and better means an improved score for those randomized to omega3 fatty acids, DHA/EPA. These analyses are adjusted for the following baseline covariates: age, gender, race, education, smoking, hypertension, congestive heart failure, and depression scale. B: Comparison of the main effects of lutein/zeaxanthin vs. no lutein/zeaxanthin. Lut/Zea: Lutein/Zeaxanthin TICS: Telephone Interview of Cognitive Status Composite score. A composite score was constructed by including the score of the TICS and all the cognitive tests by converting all test results into z-scores and then averaging the z-scores. The composite score was computed to obtain an overall score for the battery of cognitive function tests, ranging from −22 to 17, with higher scores representing better function. Telephone Interview Cognitive Status-Modified (TICS-M) is a version of the Mini Mental State Examination. The score for TICS ranges from 0 to 39 points. See supplementary methods for explanation for the scores of the other cognitive function tests. Worse means a deterioration of the score for that given nutrient and better means an improved score for those randomized to lutein/zeaxanthin. These analyses are adjusted for the following baseline covariates: age, gender, race, education, smoking, hypertension, congestive heart failure, and depression scale. C: Comparison of the main effects of high zinc vs. low zinc. TICS: Telephone Interview of Cognitive Status Composite score. A composite score was constructed by including the score of the TICS and all the cognitive tests by converting all test results into z-scores and then averaging the z-scores. The composite score was computed to obtain an overall score for the battery of cognitive function tests, ranging from −22 to 17, with higher scores representing better function. Telephone Interview Cognitive Status-Modified (TICS-M) is a version of the Mini Mental State Examination. The score for TICS ranges from 0 to 39 points. See supplementary methods for explanation for the scores of the other cognitive function tests. Worse means a deterioration of the score for that given nutrient and better means an improved score for those randomized to zinc. These analyses are adjusted for the following baseline covariates: age, gender, race, education, smoking, hypertension, congestive heart failure, and depression scale. D: Comparison of the main effects of beta-carotene vs. no beta-carotene. TICS: Telephone Interview of Cognitive Status Composite score. A composite score was constructed by including the score of the TICS and all the cognitive tests by converting all test results into z-scores and then averaging the z-scores. The composite score was computed to obtain an overall score for the battery of cognitive function tests, ranging from −22 to 17, with higher scores representing better function. Telephone Interview Cognitive Status-Modified (TICS-M) is a version of the Mini Mental State Examination. The score for TICS ranges from 0 to 39 points. See supplementary methods for explanation for the scores of the other cognitive function tests. Worse means a deterioration of the score for that given nutrient and better means an improved score for those randomized to beta-carotene. These analyses are adjusted for the following baseline covariates: age, gender, race, education, smoking, hypertension, congestive heart failure, and depression scale.
Figure 3. Results of the Odds of Having a Score of less than 30 for the Telephone Interview of Cognitive Status (TICS) for the Four Nutrients evaluated, using Repeated Measures Logistic Regression
LCPUFAs: Long Chain Polyunsaturated Fatty Acids Lut/Zea: Lutein/Zeaxanthin Telephone Interview Cognitive Status-Modified (TICS-M) is a version of the Mini Mental State Examination. The score for TICS ranges from 0 to 39 points. A dichotomous outcome from the TICS is defined as follows: 1) TICS total < 30 points defines low cognitive function and 2) TICS total ≥30 defines normal cognitive function. “Worse” means a deterioration of the TICS score (large proportion with low cognitive function) for that given nutrient and “better” means an improved TICS (smaller proportion with low cognitive function) for that given nutrient. Models were adjusted for: baseline age, sex, race, history of hypertension, education, baseline cognitive score and baseline depression score.
Comment in
- Lifestyles and Cognitive Health: What Older Individuals Can Do to Optimize Cognitive Outcomes.
Gill SS, Seitz DP. Gill SS, et al. JAMA. 2015 Aug 25;314(8):774-5. doi: 10.1001/jama.2015.9526. JAMA. 2015. PMID: 26305645 No abstract available. - Oral Nutrient Supplementation and Cognitive Function.
Renzi-Hammond LM, Miller LS, Hammond BR Jr. Renzi-Hammond LM, et al. JAMA. 2016 Feb 2;315(5):515-6. doi: 10.1001/jama.2015.16443. JAMA. 2016. PMID: 26836737 No abstract available. - Oral Nutrient Supplementation and Cognitive Function.
Yurko-Mauro K, Nelson E, Salem N Jr. Yurko-Mauro K, et al. JAMA. 2016 Feb 2;315(5):516. doi: 10.1001/jama.2015.16452. JAMA. 2016. PMID: 26836738 No abstract available. - Oral Nutrient Supplementation and Cognitive Function--Reply.
Chew EY, Launer L, Bernstein P. Chew EY, et al. JAMA. 2016 Feb 2;315(5):516-7. doi: 10.1001/jama.2015.16467. JAMA. 2016. PMID: 26836739 Free PMC article. No abstract available. - [Supplements for cognitive function unsuitable].
Holzapfel C. Holzapfel C. MMW Fortschr Med. 2015 Dec 14;157(21-22):52. doi: 10.1007/s15006-015-7616-8. MMW Fortschr Med. 2015. PMID: 26960871 German. No abstract available.
Similar articles
- Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.
Age-Related Eye Disease Study 2 Research Group. Age-Related Eye Disease Study 2 Research Group. JAMA. 2013 May 15;309(19):2005-15. doi: 10.1001/jama.2013.4997. JAMA. 2013. PMID: 23644932 Clinical Trial. - Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.
Age-Related Eye Disease Study 2 (AREDS2) Research Group; Chew EY, Clemons TE, Sangiovanni JP, Danis RP, Ferris FL 3rd, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB, Klein ML, Chandra SR, Blodi BA, Domalpally A, Friberg T, Wong WT, Rosenfeld PJ, Agrón E, Toth CA, Bernstein PS, Sperduto RD. Age-Related Eye Disease Study 2 (AREDS2) Research Group, et al. JAMA Ophthalmol. 2014 Feb;132(2):142-9. doi: 10.1001/jamaophthalmol.2013.7376. JAMA Ophthalmol. 2014. PMID: 24310343 Free PMC article. Clinical Trial. - Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.
Writing Group for the AREDS2 Research Group; Bonds DE, Harrington M, Worrall BB, Bertoni AG, Eaton CB, Hsia J, Robinson J, Clemons TE, Fine LJ, Chew EY. Writing Group for the AREDS2 Research Group, et al. JAMA Intern Med. 2014 May;174(5):763-71. doi: 10.1001/jamainternmed.2014.328. JAMA Intern Med. 2014. PMID: 24638908 Clinical Trial. - Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.
Evans JR, Lawrenson JG. Evans JR, et al. Cochrane Database Syst Rev. 2023 Sep 13;9(9):CD000254. doi: 10.1002/14651858.CD000254.pub5. Cochrane Database Syst Rev. 2023. PMID: 37702300 Free PMC article. Review. - Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questions.
Aronow ME, Chew EY. Aronow ME, et al. Curr Opin Ophthalmol. 2014 May;25(3):186-90. doi: 10.1097/ICU.0000000000000046. Curr Opin Ophthalmol. 2014. PMID: 24614146 Free PMC article. Review.
Cited by
- Recent Advances in the Synthesis of Antioxidant Derivatives: Pharmacological Insights for Neurological Disorders.
Singh K, Gupta JK, Sethi P, Mathew S, Bhatt A, Sharma MC, Saha S, Shamim, Kumar S. Singh K, et al. Curr Top Med Chem. 2024;24(22):1940-1959. doi: 10.2174/0115680266305736240725052825. Curr Top Med Chem. 2024. PMID: 39108007 Review. - Dietary supplements and disease prevention - a global overview.
Rautiainen S, Manson JE, Lichtenstein AH, Sesso HD. Rautiainen S, et al. Nat Rev Endocrinol. 2016 Jul;12(7):407-20. doi: 10.1038/nrendo.2016.54. Epub 2016 May 6. Nat Rev Endocrinol. 2016. PMID: 27150288 Review. - Associations of the intestinal microbiome with the complement system in neovascular age-related macular degeneration.
Zysset-Burri DC, Keller I, Berger LE, Largiadèr CR, Wittwer M, Wolf S, Zinkernagel MS. Zysset-Burri DC, et al. NPJ Genom Med. 2020 Sep 1;5:34. doi: 10.1038/s41525-020-00141-0. eCollection 2020. NPJ Genom Med. 2020. PMID: 32922859 Free PMC article. - Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, AlAbdulghafoor FK, Summerbell CD, Worthington HV, Song F, Hooper L. Abdelhamid AS, et al. Cochrane Database Syst Rev. 2018 Jul 18;7(7):CD003177. doi: 10.1002/14651858.CD003177.pub3. Cochrane Database Syst Rev. 2018. PMID: 30019766 Free PMC article. Updated. Review. - Marine n-3 fatty acids and cognitive change among older adults in the VITAL randomized trial.
Kang JH, Vyas CM, Okereke OI, Ogata S, Albert M, Lee IM, D'Agostino D, Buring JE, Cook NR, Grodstein F, Manson JE. Kang JH, et al. Alzheimers Dement (N Y). 2022 Apr 5;8(1):e12288. doi: 10.1002/trc2.12288. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35415212 Free PMC article.
References
- 2013 Alzheimer’s disease facts and figures. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2013;9:208–45. - PubMed
- Dangour AD, Allen E, Elbourne D, Fletcher A, Richards M, Uauy R. Fish consumption and cognitive function among older people in the UK: baseline data from the OPAL study. The journal of nutrition, health & aging. 2009;13:198–202. - PubMed
- Tully AM, Roche HM, Doyle R, et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer’s disease: a case-control study. The British journal of nutrition. 2003;89:483–9. - PubMed
- Dangour AD, Allen E, Elbourne D, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. The American journal of clinical nutrition. 2010;91:1725–32. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- Z99 EY999999/Intramural NIH HHS/United States
- ZIA EY000485-07/Intramural NIH HHS/United States
- HHS-N-260-2005-00007-C/PHS HHS/United States
- N01-EY-5-0007/EY/NEI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical